China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China flag China · Delayed Price · Currency is CNY
13.25
-0.04 (-0.30%)
Nov 17, 2026, 3:04 PM CST

SHE:300294 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,4312,0581,7342,6512,7612,645
Other Revenue
0.990.990.790.85-2.225.21
1,4322,0591,7352,6522,7592,651
Revenue Growth
-27.07%18.69%-34.58%-3.87%4.08%5.47%
Cost of Revenue
851.451,043615.971,2591,2551,187
Gross Profit
580.631,0161,1191,3931,5041,463
Selling, General & Admin
480.38648.36603.65774.85923.64969.52
Research & Development
35.8854.5566.8967.749.5859.29
Other Operating Expenses
45.8418.2317.4718.9820.8319.99
Operating Expenses
566.37742.66696.81863.9996.861,049
Operating Income
14.26272.95422.12529.38507.16414.49
Interest Expense
-2.37-1.16-0.66-0.46-0.62-10.53
Interest & Investment Income
13.8437.4242.4945.3164.9363.9
Currency Exchange Gain (Loss)
6.616.61-2.77---
Other Non Operating Income (Expenses)
9.5-2.540.87-0.434.02-8.3
EBT Excluding Unusual Items
41.84313.28462.05573.81575.49459.57
Impairment of Goodwill
-110.47-110.47-72.61-298.41--
Gain (Loss) on Sale of Investments
0.2859.9865.5885.74-10.71
Gain (Loss) on Sale of Assets
-0.465.1-0.611.30.07-0.87
Asset Writedown
-198.61-199.11-11.18-28.31-51.03-36.37
Other Unusual Items
30.7635.134.4919.597.4710.08
Pretax Income
-236.66103.88477.71353.71532443.12
Income Tax Expense
-66.84-8.7681.19105.5686.5184.84
Earnings From Continuing Operations
-169.82112.64396.53248.15445.49358.28
Minority Interest in Earnings
1.890.060.46-10.68-13.29-13.75
Net Income
-167.93112.7396.99237.47432.2344.53
Net Income to Common
-167.93112.7396.99237.47432.2344.53
Net Income Growth
--71.61%67.18%-45.06%25.45%32.48%
Shares Outstanding (Basic)
524512503505503436
Shares Outstanding (Diluted)
524512503505503436
Shares Change
4.03%1.94%-0.54%0.53%15.24%2.30%
EPS (Basic)
-0.320.220.790.470.860.79
EPS (Diluted)
-0.320.220.790.470.860.79
EPS Growth
--72.15%68.08%-45.35%8.86%29.51%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-506.09-474.15101.99554.23458.031,277
Free Cash Flow Per Share
-0.97-0.930.201.100.912.93
Dividend Per Share
0.0730.2230.3200.3000.2000.150
Dividend Growth
-76.45%-30.31%6.67%50.00%33.33%130.77%
Gross Margin
40.54%49.32%64.50%52.54%54.52%55.21%
Operating Margin
1.00%13.26%24.33%19.96%18.38%15.64%
Profit Margin
-11.73%5.47%22.88%8.95%15.67%13.00%
Free Cash Flow Margin
-35.34%-23.03%5.88%20.90%16.60%48.19%
EBITDA
189.41415.82521.95624.38600.38510.65
EBITDA Margin
13.23%20.19%30.09%23.54%21.76%19.27%
D&A For EBITDA
175.15142.8799.8294.9993.2296.16
EBIT
14.26272.95422.12529.38507.16414.49
EBIT Margin
1.00%13.26%24.33%19.96%18.38%15.64%
Effective Tax Rate
--16.99%29.84%16.26%19.15%
Revenue as Reported
1,4322,0591,7352,6522,7592,651
Advertising Expenses
-4.553.262.731.822.5